Page results
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
North Mid, UCLH and Whittington Health are running a fun, uplifting, informative event for people with sickle cell on Saturday 25th June 2022.
-
Having originally studied classics, and having first worked in publishing and in the British Library, I became a lawyer and spent ten years in commercial litigation practice in the City.
-
Researchers at UCLH have begun a study which could set the foundations for how booster COVID-19 vaccinations are delivered in the future.
-
RNOH are pleased to launch a series of regular Health and Wellbeing Information and Support Sessions to support patients following a cancer diagnosis and also during/after treatment. These…
-
Martin Jacobs joined UCLH as a non-executive director on 1 January 2020. He spent 20 years with PricewaterhouseCoopers (PwC) where he was a Partner within the Corporate Finance division.
-
Our clinical neurophysiology department performs tests which record information from the brain or the nervous system. There are two main tests performed in our outpatient department, Electroencephalogram (EEG) and Nerve conduction studies (NCS).
-
In the UK in 2020, 23 million Novo Nordisk FlexPen and FlexTouch pre-filled devices were incinerated or sent to landfill as there was no viable recycling alternative.
File results
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0244 - IT systems for digital dictation, speech recognition, outsourced transcription, video consultation and health information systems
-
FOI/2023/0247 - Treatment guidelines for Idiopathic Pulmonary Fibrosis
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0360 - Minutes of Board of Director meetings and Declarations of Interests (DoI) statements 2008-2023
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0231 - Patients seen at A&E with symptoms of taking nitrous oxide gas
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome